Cardiac Concentration is Trimetazidine, the main role is to be able to maintain cellular energy metabolism in the case of ischemia and hypoxia, for the operation of the ion pumps on the cell membrane to provide sufficient ATP, so as to maintain the normal form and function of the cell, there is no efficacy of the said. Clinically, trimetazidine is mainly used in the treatment of angina pectoris, but is generally used as a second-line drug for angina pectoris, and is only used for stabilized angina pectoris for which first-line anti-anginal drug treatment is ineffective or intolerable; in addition, it can be used as an adjunctive treatment for tinnitus and vertigo. The main adverse effects of trimetazidine are headache, vertigo, sleep disturbance, unsteady walking, but also abdominal pain, diarrhea, nausea, vomiting and other gastrointestinal reactions. Cardiac Concentration is contraindicated in patients with hypersensitivity to drug components, patients with Parkinson’s syndrome, restless legs syndrome and other movement disorders, women during pregnancy and children under 18 years of age, and patients with severe renal insufficiency. It should be noted that, once the patient in the drug during the manifestation of Parkinson’s disease and other movement disorders, must immediately stop the drug and no longer take it; other serious adverse reactions should also be immediately to the hospital, so as not to delay the condition. In the use of medication, must follow the doctor’s instructions, rational application of drugs, do not use drugs, to avoid causing serious adverse reactions.